Eli Lilly and Company (LLY)

Debt-to-assets ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands 28,527,100 29,045,400 23,730,400 24,559,900 18,320,800 17,923,600 18,158,400 18,880,500 14,737,500 14,143,800 14,692,000 15,152,900 15,346,400 15,522,400 14,736,600 16,199,600 16,586,600 16,334,600 15,064,400 13,982,300
Total assets US$ in thousands 78,714,900 75,606,900 71,874,800 63,943,500 64,006,300 57,915,500 54,814,000 53,163,000 49,489,800 47,461,500 47,063,600 46,919,300 48,806,000 48,187,000 47,809,000 46,838,300 46,633,100 43,946,000 41,967,000 41,102,800
Debt-to-assets ratio 0.36 0.38 0.33 0.38 0.29 0.31 0.33 0.36 0.30 0.30 0.31 0.32 0.31 0.32 0.31 0.35 0.36 0.37 0.36 0.34

December 31, 2024 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $28,527,100K ÷ $78,714,900K
= 0.36

The debt-to-assets ratio for Eli Lilly and Company has fluctuated over the past few years, ranging from a low of 0.29 to a high of 0.38. This ratio indicates the proportion of the company's assets financed with debt, with higher ratios suggesting a greater reliance on debt financing.

From March 31, 2020, to December 31, 2021, the debt-to-assets ratio remained relatively stable, hovering around the 0.35 mark. However, there was a slight decrease observed in the ratio from June 30, 2021, to June 30, 2022, where it dropped from 0.31 to 0.30.

The ratio increased notably in the following quarters, with spikes observed on March 31, 2023, and September 30, 2024, when it reached 0.38. However, there were also periods of decline seen, such as the decrease from June 30, 2022, to September 30, 2022, where the ratio decreased from 0.31 to 0.30.

Overall, the debt-to-assets ratio for Eli Lilly and Company has shown some fluctuations but has generally remained within a moderate range, indicating a balanced mix of debt and assets in the company's capital structure.


See also:

Eli Lilly and Company Debt to Assets (Quarterly Data)